This content is from: Patents

Bass and Spangenberg double down on IPR strategy

Hedge fund manager Kyle Bass and IP Nav’s Erich Spangenberg have filed a second inter partes review petition against a patent owned by Acorda Therapeutics, as part of a strategy BIO said had “opened a new door to abuse of the US patent system”

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Related

Instant access to all of our content. Membership Options | One Week Trial